These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 14768038)

  • 1. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
    Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular-mass tumor-associated antigens: rate of lymphoid infiltration and distribution of T lymphocytes in tumors.
    Ben-Hur H; Kossoy G; Zandbank J; Zusman I
    Int J Mol Med; 2002 Apr; 9(4):425-30. PubMed ID: 11891540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
    Valzasina B; Piconese S; Guiducci C; Colombo MP
    Cancer Res; 2006 Apr; 66(8):4488-95. PubMed ID: 16618776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
    Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
    Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation.
    Kullberg MC; Hay V; Cheever AW; Mamura M; Sher A; Letterio JJ; Shevach EM; Piccirillo CA
    Eur J Immunol; 2005 Oct; 35(10):2886-95. PubMed ID: 16180248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-localized ligation of CD3 and CD28 with systemic regulatory T-cell depletion induces potent innate and adaptive antitumor responses.
    Lee CH; Chiang YH; Chang SE; Chong CL; Cheng BM; Roffler SR
    Clin Cancer Res; 2009 Apr; 15(8):2756-66. PubMed ID: 19318495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
    Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
    J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a CD4+CD25+ T cell subset committed in vivo to suppress antigen-specific T cell responses without additional stimulation.
    Nolte-'t Hoen EN; Wagenaar-Hilbers JP; Boot EP; Lin CH; Arkesteijn GJ; van Eden W; Taams LS; Wauben MH
    Eur J Immunol; 2004 Nov; 34(11):3016-27. PubMed ID: 15376196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
    Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta.
    Somasundaram R; Jacob L; Swoboda R; Caputo L; Song H; Basak S; Monos D; Peritt D; Marincola F; Cai D; Birebent B; Bloome E; Kim J; Berencsi K; Mastrangelo M; Herlyn D
    Cancer Res; 2002 Sep; 62(18):5267-72. PubMed ID: 12234995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
    Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated CD4+ CD25+ T cells suppress antigen-specific CD4+ and CD8+ T cells but induce a suppressive phenotype only in CD4+ T cells.
    Dieckmann D; Plöttner H; Dotterweich S; Schuler G
    Immunology; 2005 Jul; 115(3):305-14. PubMed ID: 15946248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.
    Azuma T; Takahashi T; Kunisato A; Kitamura T; Hirai H
    Cancer Res; 2003 Aug; 63(15):4516-20. PubMed ID: 12907625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens.
    Golgher D; Jones E; Powrie F; Elliott T; Gallimore A
    Eur J Immunol; 2002 Nov; 32(11):3267-75. PubMed ID: 12555672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cyclophosphamide and soluble tumor-associated antigens on lymphoid infiltration, proliferative activity and rate of apoptosis in chemically-induced rat mammary tumors.
    Ben-Hur H; Kossoy G; Tendler Y; Kossoy N; Zusman I
    In Vivo; 2002; 16(5):287-92. PubMed ID: 12494865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune compartmentalization of T cell subsets in chemically-induced breast cancer.
    Fahmi T; Esendagli G; Yilmaz G; Kansu E; Guc D
    Scand J Immunol; 2010 Oct; 72(4):339-48. PubMed ID: 20883319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells.
    Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N
    Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.